Björn Wiman

Q: What Schools Are Affiliated With Björn Wiman

Björn Wiman is affiliated with the following schools: University of Notre Dame, Umeå University, Karolinska Institute

Björn Wiman's AcademicInfluence.com Rankings

Björn Wiman

Philosophy

#6626

World Rank

#9690

Historical Rank

Logic

#3769

World Rank

#4977

Historical Rank

philosophy Degrees

Björn Wiman

Biology

#8972

World Rank

#12121

Historical Rank

Biochemistry

#1335

World Rank

#1456

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Björn Wiman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Björn Wiman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION (1987) (1626)
Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. (1985) (1437)
Association of apolipoprotein E genotypes with lipid levels and coronary risk. (2007) (731)
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. (1993) (639)
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. (1983) (530)
Molecular mechanism of physiological fibrinolysis (1978) (375)
Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. (1991) (349)
Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. (1990) (315)
On the kinetics of the reaction between human antiplasmin and plasmin. (1978) (314)
Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility (2005) (286)
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. (1986) (282)
Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. (1983) (258)
On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. (1979) (249)
The role of the fibrinolytic system in deep vein thrombosis. (1985) (226)
Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. (1972) (223)
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. (2000) (222)
The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene (1999) (222)
Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. (1977) (214)
Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. (1986) (205)
Haemostatic function in myocardial infarction. (1986) (199)
Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease (1995) (196)
The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. (1977) (186)
Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. (2004) (185)
Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. (1984) (185)
The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. (1990) (179)
On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin. (1979) (178)
Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction. (2004) (175)
Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma (1988) (166)
Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. (1973) (160)
Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. (1970) (160)
Stability of Plasminogen Activator Inhibitor 1 (PAI-1) (1989) (147)
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. (2002) (141)
Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the S heep study (1999) (140)
Haplotypes extending across ACE are associated with Alzheimer's disease. (2003) (133)
Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. (2003) (129)
Determination of Soluble Fibrin in Plasma by a Rapid and Quantitative Spectrophotometric Assay (1986) (127)
Primary structure of the B-chain of human plasmin. (1977) (126)
Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. (2008) (118)
On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin. (1978) (118)
Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. (1997) (117)
Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. (2003) (116)
Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. (1979) (111)
Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. (1988) (110)
On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. (1978) (109)
The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. (1990) (105)
Affinity-chromatographic purification of human α2-antiplasmin (1980) (103)
4G/5G Polymorphism of PAI-1 Gene Promoter and Fibrinolytic Capacity in Patients with Deep Vein Thrombosis (1998) (100)
Receptors for human plasminogen on gram-negative bacteria (1990) (95)
The Significance of Hypofibrinolysis for the Risk of Recurrence of Venous Thromboembolism (1996) (91)
Primary structure of peptides released during activation of human plasminogen by urokinase. (1973) (91)
Association of TNF-α serum levels and TNFA promoter polymorphisms with risk of myocardial infarction (2006) (89)
Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. (1975) (87)
Fast-acting plasmin inhibitor in human plasma. (1978) (86)
Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene (1995) (85)
Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. The SHEEP Study Group. (1999) (81)
Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. (1998) (77)
The Fast Inhibitor of Tissue Plasminogen Activator in Plasma During Pregnancy (1984) (77)
Impaired fibrinolysis and risk of thromboembolism. (1991) (76)
New receptor for human plasminogen on gram positive cocci (1989) (74)
Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men (1993) (69)
Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. (1998) (62)
Preparation and isolation of the S‐carboxymethyl derivative chains of human fibrinogen (1971) (61)
Plasma fibrinolytic activity in patients undergoing major abdominal surgery. (1985) (60)
Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. (2006) (57)
Influence of Metoprolol Treatment on Sympatho-Adrenal Activation of Fibrinolysis (1990) (55)
Haemostatic Factors and Inhibitors and Coronary Artery Bypass Grafting: Preoperative Alterations and Relations to Graft Occlusion (1994) (54)
On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or α2-antiplasmin (1980) (54)
Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. (2000) (53)
Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects (1993) (53)
A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. (2004) (53)
PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction (2003) (51)
On the primary structure of human plasminogen and plasmin. Purification and characterization of cyanogen-bromide fragments. (1975) (49)
The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. (2005) (49)
Inactivation of tissue plasminogen activator in plasma (1988) (46)
Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study In Stockholm (APSIS). A comparison with healthy controls (1997) (45)
Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis (2006) (44)
Fibrinolytic activity in plasma and deep vein thrombosis after major abdominal surgery. (1983) (44)
Two types of receptors for human plasminogen on group G streptococci (1992) (43)
Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen. (1982) (41)
ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation (2004) (40)
The G‐455A polymorphism of the fibrinogen BΒ‐gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women (2002) (40)
Comparison of plasminogen activator inhibitor activity and antigen in plasma samples. (1987) (39)
[32] Human α2-antiplasmin☆ (1981) (39)
Identification of a PAI-1 binding site in vitronectin. (1994) (39)
Coagulation Factor V (Arg506 → Gln) Mutation and Early Saphenous Vein Graft Occlusion after Coronary Artery Bypass Grafting (1998) (39)
Evidence for a Discrete Binding Protein of Plasminogen Activator Inhibitor in Plasma (1988) (38)
Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP) (2007) (38)
Amino‐acid sequence of human α2‐antiplasmin (1987) (37)
Determination of plasmin-alpha 2-antiplasmin complex in plasma samples by means of a radioimmunoassay. (1983) (36)
On the Relationship Between Different Molecular Forms of the Fast Inhibitor of Tissue Plasminogen Activator (1987) (35)
Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin. (2003) (35)
Affinity-chromatographic purification of human alpha 2-antiplasmin. (1980) (34)
Haemostatic function in patients undergoing coronary artery bypass grafting: peroperative perturbations and relations to saphenous vein graft closure. (2000) (34)
Predictive value of fibrinolytic factors in coronary heart disease. (1999) (34)
The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis. (2000) (34)
Soluble fibrin: A predictor for the development and outcome of multiple organ failure (1994) (33)
Correlations between fibrinolytic function and acute myocardial infarction. (1990) (33)
Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. (1997) (32)
Immunological Relationship Between Plasminogen Activator Inhibitors from Different Sources (1987) (32)
The physiological inhibitors of blood coagulation and fibrinolysis : proceedings of a round-table conference held at the University of Leuven, Belgium, July 22-23, 1978 (1979) (32)
PAI‐1 stability: the role of histidine residues (2000) (31)
A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance. (1985) (31)
Complex formation between plasminogen activator inhibitor 1 and vitronectin in purified systems and in plasma. (1990) (30)
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. (1996) (30)
A new simple method for determination of C1-esterase inhibitor activity in plasma. (1983) (30)
Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery. (1985) (29)
Increased Incorporation of Antiplasmin Into the Fibrin Network in Patients With Type 1 Diabetes (2014) (29)
Purification and characterization of human ci-esterase inhibitor (1982) (28)
Molecular Mechanisms of Fibrinolysis in Man (1978) (27)
The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL‐6 concentration (2007) (27)
Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium. (1989) (26)
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity (2007) (25)
Genetic factors determining thrombosis and fibrinolysis. (1992) (24)
Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s. (2005) (23)
On the structure of the stable complex between plasmin and α2‐antiplasmin (1982) (22)
Amino-acid sequence of the cyanogen-bromide fragment from human plasminogen that forms the linkage between the plasmin chains. (1975) (21)
Plasminogen activator inhibitor 1 in thrombotic disease (1996) (20)
Angiostatin fragments in urine from patients with malignant disease. (1999) (19)
Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule. (1998) (19)
Human fibrinogen: Some characteristics of its S-carboxymethyl derivative chains☆ (1972) (18)
Circular dichroism studies on α2-antiplasmin and its interactions with plasmin and plasminogen (1982) (18)
Release of tissue plasminogen activator during reperfusion after different times of ischaemia in isolated, perfused rat hearts. (1996) (18)
Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis. (1985) (17)
Increased expression of α‐enolase in c‐jun transformed rat fibroblasts without increased activation of plasminogen (1997) (17)
Partial Primary Structure of Human α2-Antiplasmin – Homology with Other Plasma Protease Inhibitors (1982) (16)
Structural and circular-dichroism studies on the interaction between human C1-esterase inhibitor and C1s. (1983) (16)
Monoclonal Antibodies Towards the Fast Inhibitor of Tissue Plasminogen Activator from Human Plasma and Serum (1986) (15)
Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostacyclin metabolites (1988) (15)
Stability of plasminogen activator inhibitor‐1: role of tyrosine221 (1998) (14)
Oxidative stress and release of tissue plasminogen activator in isolated rat hearts. (1997) (13)
Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. (2007) (13)
Decreased risk for myocardial infarction and lower tumor necrosis factor-alpha levels in carriers of variants of the PDCD1 gene. (2006) (13)
Amino acid sequence around the arginyl-valyl bond in plasminogen which is cleaved during the second step of the activation process. (1975) (13)
Disseminated intravascular coagulation in neurosurgical patients: diagnosis by new laboratory methods. (1992) (12)
Soluble fibrin in plasma as a sign of activated coagulation in patients with pregnancy complications (1998) (11)
Changes in antigenic structure and conformation of alpha 2-antiplasmin induced by interaction with plasmin. (1980) (11)
The Bβ-sheet in the PAI-1 Molecule Plays an Important Role for Its Stability (2000) (10)
On the structure of the N-terminal fragment of human plasminogen obtained after cleavage with cyanogen bromide (1972) (10)
Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-β1-42 and plasma apolipoprotein levels (2006) (10)
Studies on the interaction between plasminogen activator inhibitor-1 and vitronectin (1992) (10)
The interaction between plasminogen and antiplasmin variants as studied by surface plasmon resonance. (2006) (10)
On the reaction of plasmin or plasmin-streptokinase complex with aprotinin or alpha 2-antiplasmin. (1980) (10)
The G-455A polymorphism of the fibrinogen Bbeta-gene relates to plasma fibrinogen in male cases, but does not interact with environmental factors in causing myocardial infarction in either men or women : Journal of Internal Medicine (2002) (10)
The role of His143 for the pH-dependent stability of plasminogen activator inhibitor-1 (1999) (10)
Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin. (1978) (9)
Binding of tissue-type plasminogen activator (t-PA) to Neisseria meningitidis and Haemophilus influenzae. (1994) (9)
Enhancement of t-PA-mediated plasminogen activation by bacterial surface receptors (1995) (9)
Inactivation of antiplasmin at low pH: evidence for the formation of latent molecules. (2004) (8)
Prediction of deep vein thrombosis after extensive abdominal operations by the quotient between plasmin-alpha 2-antiplasmin complex and fibrinogen concentration in plasma. (1985) (7)
Amino-acid sequence of human alpha 2-antiplasmin. (1987) (6)
The role of His(143) for the pH-dependent stability of plasminogen activator inhibitor-1. (1999) (6)
Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance (1997) (6)
Genetic variation at the plasminogen activator inhibitor-1 (PAI-1) locus (1990) (6)
Amino-acid sequence of human a2-antiplasmin (1987) (6)
The Non-covalent interaction between plasmin and α2-antiplasmin (1989) (6)
Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region (1999) (6)
Antiplasmin, the Fast-Reacting Plasmin Inhibitor of Human Plasma (1977) (5)
Possibilities of DNA Analysis for the Detection of Predisposition to Thrombotic Disease (1992) (5)
Purification of Tissue Activator Using Affinity Adsorption on Fibrin and Hydrophobic Interaction Chromatography. Effect of Fibrin on the Enzymatic Properties of the Activator (1975) (5)
Purification and partial primary structure of cyanogen bromide fragments from human α2-antiplasmin (1982) (4)
On the structure of the stable complex between plasmin and alpha-2-antiplasmin. (1982) (4)
Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure. (2001) (3)
On the Primary Structure of Human Plasminogen and Plasmin, Cyanogen Bromide Fragments (1975) (3)
Modification of a tyrosine residue in the carboxyterminal portion of human alpha2-antiplasmin. (1985) (3)
α and β-adrenergic influences on the tissue and urokinase plasminogen activator systems (1999) (3)
ALLELE SPECIFIC DIFFERENTIAL BINDING OF HEPG2 NUCLEAR EXTRACTS TO A COMMON POLYMORPHISM IN THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) PROMOTER WHICH IS ASSOCIATED WITH ALTERED PLASMA PAI-1 LEVELS (1991) (3)
Comparison of the partial primary structure of human alpha2-antiplasmin with other plasma protease inhibitors (1983) (3)
Acute effects with reference to thrombogenicity and liver toxicity after injection of different coagulation factor concentrates. (1989) (3)
Low PAI‐1 activity in relation to inflammatory parameters, insulin profile and body mass index (2008) (2)
Purification and characterization of human C1-esterase inhibitor. (1982) (2)
Circular dichroism studies on alpha 2-antiplasmin and its interactions with plasmin and plasminogen. (1982) (2)
A new method measuring the interaction between von Willebrand factor and coagulation factor VIII. (2011) (2)
A coagulo-radioimmunometric assay for the quantitation of fibrin monomer in human plasma. Principles and development of the method. (1979) (2)
IMMUNOHISTOCHEMICAL LOCALIZATION OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI) IN TISSUE (1987) (2)
Discovery of PAI-1 in plasma. (2000) (2)
Fibrinolytic response after injection of desamino-d-arginine vasopressin (dDAVP) in healthy volunteers (1992) (2)
Partial Primary Structure Of Human α2-Antiplasmin (1981) (2)
Structures of importance for the stability of antiplasmin as studied by site-directed mutagenesis. (2006) (1)
Enzymatic properties of t-PA/α2-macroglobulin complexes (1991) (1)
Hemostasis and anticoagulation in total artificial heart implantation (1985) (1)
Identification of an 18 basepair deletion in the PAI-1 gene promoter region in a family with thrombotic disease (1997) (1)
Purification and caracterization of a plasminogen binding protein from haemophilus influenzae (1994) (1)
EVIDENCE FOR A PLASMINOGEN ACTIVATOR INHIBITOR BINDING PROTEIN IN PLASMA (1987) (1)
No effect of factor Xa or tissue thromboplastin and factor VII on the activation of plasminogen. (1976) (1)
104 Fibrinogen enhances the poly-lysine stimulated plasminogen activation by tPA (1988) (0)
ON THE KINETICS OF THE INHIBITION OF PLASMINOGEN ACTIVATORS BY THE PLASMINOGEN ACTIVATOR INHIBITOR PAI-1 (1987) (0)
A COMMON POLYMORPHISM IN THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) PROMOTER SHOWS ALLELE SPECIFIC DIFFERENTIAL BINDING TO HEPG2 NUCLEAR EXTRACTS AND IS ASSOCIATED WITH ALTERED PLASMA PAI-1 LEVELS (1991) (0)
Search for mutations in the genes for FV and FVIII with a possible predisposition to APC resistance (1996) (0)
Conformational Alterations of α2-Antiplasmin Induced by Complex Formation with Plasmin (1979) (0)
Response to Comment on Ågren et al. Increased Incorporation of Antiplasmin Into the Fibrin Network in Patients With Type 1 Diabetes. Diabetes Care 2014;37:2007–2014 (2014) (0)
A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY BETWEEN COLLAGEN AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES (2007) (0)
Purification and partial primary structure of cyanogen bromide fragments from human alpha 2-antiplasmin. (1982) (0)
New Receptor For Human Plasminogen On Gram Positive Cocci (2007) (0)
Haemostatic function in myocardial infarction Patients and methods STUDY (2005) (0)
Effect of lipoprotein (a) on the activation of fibrinolytic system (1994) (0)
Stimulation of F-Cell Production in Patients with Sickle-Cell Anemia Treated with Cytarabine or Hydroxyurea 1571 (1985) (0)
ON DIFFERENT MOLECULAR EORMS OE PLASMINOGEN ACTIVATOR INHIBITOR (1987) (0)
Purification of α2-Antiplasmin by a Single-Step Affinity Chromatographic Procedure (1979) (0)
On the Mechanism of Action of α2-Antiplasmin (1979) (0)
A COACLZO-lUDIOIMMUNOMBTRIC ASSAY FOR THE QUANTITXTION OF FIBRIN MONOMER IN HDMAN PLASMA. PRINCIPLES AND DEVELOPZNT OF THE METHOD (1979) (0)
275 Demonstration of a plasminogen activator inhibitor binding protein in human plasma and its partial purification (1988) (0)
The importance of the G/A−455 polymorphism of the β-fibrinogen gene in relation to myocardial infarction risk (2000) (0)
[New methods accelerate the development of thrombolytic agents]. (1991) (0)
Evidence for 'second-site' interactions (2005) (0)
224 Effect of fibrin on the reaction between plasminogen activators and plasminogen activator inhibitor 1 (1988) (0)
altered levels of plasma plasminogen activator inhibitor-1 activity Genetic variation at the plasminogen activator inhibitor-1 locus is associated with (2011) (0)
72 On the high molecular weight form of plasminogen activator inhibitor 1 (1988) (0)
Impaired fibrinolytic function in coronary heart disease (1990) (0)
The interaction between PAI-1 and vitronectin (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Björn Wiman?

Björn Wiman is affiliated with the following schools:

Björn Wiman's Academic­Influence.com Rankings

Why Is Björn Wiman Influential?

Björn Wiman's Published Works

Published Works

What Schools Are Affiliated With Björn Wiman?

Björn Wiman's AcademicInfluence.com Rankings